SG11201907891XA - Combination therapy for the treatment or prevention of tumours - Google Patents
Combination therapy for the treatment or prevention of tumoursInfo
- Publication number
- SG11201907891XA SG11201907891XA SG11201907891XA SG11201907891XA SG11201907891XA SG 11201907891X A SG11201907891X A SG 11201907891XA SG 11201907891X A SG11201907891X A SG 11201907891XA SG 11201907891X A SG11201907891X A SG 11201907891XA SG 11201907891X A SG11201907891X A SG 11201907891XA
- Authority
- SG
- Singapore
- Prior art keywords
- queensland
- international
- tumours
- yungaburra
- penda
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 230000003902 lesion Effects 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 241001559589 Cullen Species 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 241001675335 Taringa Species 0.000 abstract 1
- 230000000981 bystander Effects 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
WO 18/ 17 055 9 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIPO I PCT ill 1111u°11101VIIIVIIIVIIIolo VIII Em ono imio oimIE (10) International Publication Number WO 2018/170559 Al Untreated lesion 15 1,tg Compound 1 • (51) International Patent Classification: A61K 31/336 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/AU2018/050277 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2017901027 23 March 2017 (23.03.2017) AU (71) Applicant: QBIOTICS LIMITED [AU/AU]; 7 Penda Street, Yungaburra, Queensland 4884 (AU). (72) Inventors: REDDELL, Paul Warren; 7 Penda Street, Yungaburra, Queensland 4884 (AU). CULLEN, Jason Kingsley; Unit 16, 175-205 Thornside Road, Thornside, Queensland 4159 (AU). BOYLE, Glen Mathew; 65 Hills- don Road, Taringa, Queensland 4068 (AU). PARSONS, Peter Gordon; 317 Swann Road, St Lucia, Queensland 4067 (AU). GORDON, Victoria Anne; 7 Penda Street, Yungaburra, Queensland 4884 (AU). (74) Agent: GRIFFITH HACK; GPO Box 1285, Melbourne, Victoria 3001 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: COMBINATION THERAPY FOR THE TREATMENT OR PREVENTION OF TUMOURS (57) : The present invention relates to a combination therapy for tu- mours comprising the administration of an epoxytigliane compound and an im- Fig 7A mune checkpoint inhibitor. In particular embodiments, there is a method of treat- B16-F10-OVA ing a tumour and/or treating or preventing one or more bystander tumours with the therapy. Pharmaceutical compositions and kits containing epoxytigliane compounds and immune checkpoint inhibitors are also described. a-PD-1 or a-CTLA-4 (200 py) i.p. 5 5 5 (...) measure treated and I I I I untreated lesions day -2 0 2 4 6
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901027A AU2017901027A0 (en) | 2017-03-23 | Combination Therapy | |
| PCT/AU2018/050277 WO2018170559A1 (en) | 2017-03-23 | 2018-03-23 | Combination therapy for the treatment or prevention of tumours |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907891XA true SG11201907891XA (en) | 2019-09-27 |
Family
ID=63583892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907891XA SG11201907891XA (en) | 2017-03-23 | 2018-03-23 | Combination therapy for the treatment or prevention of tumours |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11213506B2 (en) |
| EP (1) | EP3600281B1 (en) |
| JP (1) | JP6905075B2 (en) |
| KR (1) | KR102228055B1 (en) |
| CN (1) | CN110461324A (en) |
| AU (1) | AU2018238202B2 (en) |
| BR (1) | BR112019019748A2 (en) |
| CA (1) | CA3056685C (en) |
| DK (1) | DK3600281T3 (en) |
| EA (1) | EA201992220A1 (en) |
| ES (1) | ES2953575T3 (en) |
| FI (1) | FI3600281T3 (en) |
| HR (1) | HRP20230936T1 (en) |
| HU (1) | HUE063299T2 (en) |
| IL (1) | IL269522B2 (en) |
| LT (1) | LT3600281T (en) |
| MX (1) | MX2019011221A (en) |
| MY (1) | MY197427A (en) |
| NZ (1) | NZ756754A (en) |
| PH (1) | PH12019502132A1 (en) |
| PL (1) | PL3600281T3 (en) |
| PT (1) | PT3600281T (en) |
| RS (1) | RS64472B1 (en) |
| SG (1) | SG11201907891XA (en) |
| SI (1) | SI3600281T1 (en) |
| UA (1) | UA125614C2 (en) |
| WO (1) | WO2018170559A1 (en) |
| ZA (1) | ZA201906001B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2634469C (en) * | 2005-12-23 | 2012-08-21 | Qbiotics Limited | Tiglien-3-one derivatives |
| JP6656733B2 (en) | 2013-08-05 | 2020-03-04 | ツイスト バイオサイエンス コーポレーション | Newly synthesized gene library |
| US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| JP6982362B2 (en) | 2015-09-18 | 2021-12-17 | ツイスト バイオサイエンス コーポレーション | Oligonucleic acid mutant library and its synthesis |
| CN108698012A (en) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | Flexible substrates for nucleic acid synthesis |
| KR102217487B1 (en) | 2016-09-21 | 2021-02-23 | 트위스트 바이오사이언스 코포레이션 | Nucleic acid-based data storage |
| CA3054303A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| CA3066744A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| SG11202002194UA (en) | 2017-09-11 | 2020-04-29 | Twist Bioscience Corp | Gpcr binding proteins and synthesis thereof |
| WO2019079769A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
| WO2019222706A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| JP2022522668A (en) | 2019-02-26 | 2022-04-20 | ツイスト バイオサイエンス コーポレーション | Mutant nucleic acid library for antibody optimization |
| SG11202110599RA (en) * | 2019-04-12 | 2021-10-28 | QBiotics Pty Ltd | Method of treating tumours |
| EP3986394A4 (en) * | 2019-06-19 | 2022-08-10 | QBiotics Pty Ltd | Biofilm disruption |
| AU2020298294A1 (en) | 2019-06-21 | 2022-02-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| IL293670A (en) * | 2019-12-09 | 2022-08-01 | Twist Bioscience Corp | Variant nucleic acid libraries for adenosine receptors |
| KR20220151333A (en) | 2021-05-06 | 2022-11-15 | 한국과학기술연구원 | Visible light-activatable nanoparticles for cancer immunotherapy and use thereof |
| WO2023115123A1 (en) * | 2021-12-21 | 2023-06-29 | QBiotics Pty Ltd | Crystalline intermediates |
| WO2023154984A1 (en) * | 2022-02-17 | 2023-08-24 | QBiotics Pty Ltd | Combination therapies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8022103B2 (en) * | 2005-07-13 | 2011-09-20 | Salvia Sciences, Inc. | Ester prodrugs of prostratin and related phorbol compounds |
| CA2634469C (en) * | 2005-12-23 | 2012-08-21 | Qbiotics Limited | Tiglien-3-one derivatives |
| HUE043272T2 (en) * | 2013-04-18 | 2019-08-28 | Qbiotics Ltd | Methods and compositions for wound healing |
| WO2015133596A1 (en) * | 2014-03-07 | 2015-09-11 | 国立大学法人京都大学 | Composition for cell culture |
| EP3169340B1 (en) | 2014-07-16 | 2020-09-02 | Institut Gustave Roussy | Combination of oncolytic virus with immune checkpoint modulators |
| EP3204040B1 (en) | 2014-10-10 | 2021-12-08 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonists and checkpoint inhibitors |
| CN104926758A (en) * | 2015-05-22 | 2015-09-23 | 南京泽朗医药科技有限公司 | Preparation method of Baliospermin and application of Baliospermin in anti-leukemia medicaments |
| EP3331851A1 (en) * | 2015-08-03 | 2018-06-13 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
-
2018
- 2018-03-23 LT LTEPPCT/AU2018/050277T patent/LT3600281T/en unknown
- 2018-03-23 FI FIEP18770812.8T patent/FI3600281T3/en active
- 2018-03-23 CN CN201880019617.4A patent/CN110461324A/en active Pending
- 2018-03-23 EA EA201992220A patent/EA201992220A1/en unknown
- 2018-03-23 DK DK18770812.8T patent/DK3600281T3/en active
- 2018-03-23 NZ NZ756754A patent/NZ756754A/en unknown
- 2018-03-23 PL PL18770812.8T patent/PL3600281T3/en unknown
- 2018-03-23 IL IL269522A patent/IL269522B2/en unknown
- 2018-03-23 US US16/496,333 patent/US11213506B2/en active Active
- 2018-03-23 ES ES18770812T patent/ES2953575T3/en active Active
- 2018-03-23 EP EP18770812.8A patent/EP3600281B1/en active Active
- 2018-03-23 HU HUE18770812A patent/HUE063299T2/en unknown
- 2018-03-23 SI SI201830978T patent/SI3600281T1/en unknown
- 2018-03-23 RS RS20230697A patent/RS64472B1/en unknown
- 2018-03-23 SG SG11201907891XA patent/SG11201907891XA/en unknown
- 2018-03-23 CA CA3056685A patent/CA3056685C/en active Active
- 2018-03-23 AU AU2018238202A patent/AU2018238202B2/en active Active
- 2018-03-23 BR BR112019019748A patent/BR112019019748A2/en active Search and Examination
- 2018-03-23 MY MYPI2019005163A patent/MY197427A/en unknown
- 2018-03-23 MX MX2019011221A patent/MX2019011221A/en unknown
- 2018-03-23 PT PT187708128T patent/PT3600281T/en unknown
- 2018-03-23 WO PCT/AU2018/050277 patent/WO2018170559A1/en active Application Filing
- 2018-03-23 KR KR1020197031149A patent/KR102228055B1/en active IP Right Grant
- 2018-03-23 JP JP2019552088A patent/JP6905075B2/en active Active
- 2018-03-23 UA UAA201910449A patent/UA125614C2/en unknown
- 2018-03-23 HR HRP20230936TT patent/HRP20230936T1/en unknown
-
2019
- 2019-09-11 ZA ZA2019/06001A patent/ZA201906001B/en unknown
- 2019-09-17 PH PH12019502132A patent/PH12019502132A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907891XA (en) | Combination therapy for the treatment or prevention of tumours | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201809162XA (en) | 6-aminopyridin-3-yl thiazoles as modulators of ror?t |